As artificial intelligence (AI) reshapes industries across the global economy, one of the most profound—and potentially transformative—intersections is emerging in the field of regenerative medicine. Long regarded as the frontier of biological science, regenerative therapies such as stem cell treatments, amniotic tissue applications, and advanced biologics are now experiencing a pivotal acceleration thanks to AI's analytical and educational capabilities.
The head of the FDA is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots. "We're taking a look. I can't comment on any particular application. As you know, we have a bunch of applications for those booster shots," FDA Commissioner Dr. Marty Makary says many healthcare workers did not get the last round of COVID-19 vaccine booster shots, calling it "a bit of a public trust problem."
Experts say Health and Human Services Secretary Robert F. Kennedy Jr. and other health officials’ pronouncements to lower drug costs overlooks major key issues.
Teams of health care providers called Accountable Care Organizations participating in the Medicare Shared Savings Program have saved Medicare between $4.1 billion and $8.1 billion from 2012 through 2019, according to a new study from Weill Cornell Medicine investigators.
AI can process diverse data sources—ranging from medical images to genetic information to patient voice recordings—to help doctors make more informed decisions. While processing this data individually can deliver important insights, combining them can create a clearer, more complete picture of a patient's health.